Prostate cancer is the most common non-skin cancer in men globally and the second most common urological cancer in India. The key to long-term survival lies in early detection. When caught at Stage 1 or 2, prostate cancer treatment is almost always curable with a 98%+ 10-year survival rate. This guide covers everything a patient needs to know.
What Is Prostate Cancer?
Prostate cancer is a malignant growth arising from the glandular cells of the prostate gland — a walnut-sized gland located below the bladder in men. Most prostate cancers are adenocarcinomas that grow slowly, though high-grade (Gleason 8-10) cancers can be aggressive. PSA (Prostate-Specific Antigen) blood test and digital rectal examination (DRE) are the primary screening tools.
Prostate Cancer Screening — PSA Test Guidelines 2026
The American Cancer Society 2025 guidelines recommend initiating screening discussions at:
- Age 40-45 for men with strong family history (father or brother with prostate cancer)
- Age 45 for men of South Asian descent, who have higher risk
- Age 50 for average-risk men with greater than 10-year life expectancy
A PSA level above 4.0 ng/mL warrants further evaluation. A PSA of 2.5-4.0 ng/mL with a rising velocity or abnormal MRI also requires biopsy consideration.
Prostate Cancer Risk Categories and Staging
EAU 2025 Risk Classification
- Low Risk: PSA <10, Gleason 6, T1-T2a — Active surveillance or definitive treatment
- Intermediate Risk: PSA 10-20 or Gleason 7 — Radical prostatectomy or radiotherapy
- High Risk: PSA >20 or Gleason 8-10 — Multimodal therapy recommended
- Locally Advanced (T3/T4): Combined radiation plus prolonged hormone therapy
- Metastatic (M1): ADT combined with chemotherapy or novel hormonal agents
Advanced Prostate Cancer Treatment Options —
1. Active Surveillance
For low-risk, early-stage prostate cancer, active surveillance (regular PSA, MRI, and repeat biopsy) is a safe alternative to immediate treatment, avoiding side effects while monitoring closely for progression.
2. Radical Prostatectomy (Robotic-Assisted)
Surgical removal of the prostate. Robotic-assisted laparoscopic prostatectomy (RALP) offers 3D visualization and precise nerve-sparing for preservation of urinary continence and sexual function. RALP is the standard for localized intermediate and high-risk disease in fit patients.
3. Radiation Therapy
External Beam Radiation Therapy (IMRT/SBRT) and Brachytherapy (radioactive seed implants) deliver equivalent cancer control to surgery for localized disease, with a different side effect profile. The choice depends on patient factors, anatomy, and preference.
4. Hormone Therapy (Androgen Deprivation Therapy)
Prostate cancer is testosterone-dependent. ADT with LHRH agonists (leuprolide, goserelin) or LHRH antagonists (degarelix, relugolix) reduces testosterone to castrate levels, controlling cancer growth. ADT is the backbone of treatment for locally advanced and metastatic prostate cancer.
5. Novel Hormonal Agents (2026 Standard of Care)
Enzalutamide, abiraterone, apalutamide, and darolutamide have dramatically improved survival in metastatic disease. The ARCHES trial 5-year update (NEJM 2025) shows 50% improvement in overall survival with enzalutamide + ADT versus ADT alone in metastatic castration-sensitive prostate cancer.
6. PSMA PET-CT Guided Management
PSMA PET-CT (Prostate-Specific Membrane Antigen Positron Emission Tomography) is now the most sensitive imaging modality for prostate cancer staging and biochemical recurrence detection — detecting micro-metastases missed by conventional bone scan and CT scan.
Frquently Asked Questions: –
Q1 : What is the survival rate of prostate cancer?
A: Five-year survival: Stage 1–2 exceeds 98%, Stage 3 around 90–95%, and Stage 4 about 30–35%, improving with newer treatments.
Q2: What is Stage 4 prostate cancer treatment?
A: Stage 4 prostate cancer is managed using ADT, chemotherapy, or hormonal agents; though not curable, patients often achieve long-term disease control.
Q3: Is prostate cancer hereditary?
A: Yes. Men with a first-degree relative have 2–3× higher risk; BRCA1/BRCA2 mutations further increase risk and influence treatment decisions.
Q4: How is prostate cancer diagnosed?
A: Diagnosis includes PSA test, digital rectal exam, mpMRI, and MRI-guided biopsy with 12–16 cores targeting PI-RADS suspicious areas.
Why Choose Dr. Vikas Singh for Prostate Cancer in Indore?
Dr. Vikas singh , MCh Urology with uro-oncology specialization, is skilled in laparoscopic and nerve-sparing prostatectomy. He offers multidisciplinary tumour board consultations, uses PSMA PET-CT-guided protocols, and provides personalized treatment plans focused on effective cancer management while prioritizing patients’ quality of life and long-term wellbeing.
Final Words
Take control of your prostate health today. Book a consultation with Dr. Vikas Singh in Indore for accurate diagnosis, advanced treatment, and personalized care. Early detection saves lives—don’t delay. Call now or schedule your appointment online for expert prostate cancer management and better long-term outcomes.
Reach us at: Dr. Vikas Singh, Urologist
